The STI model demonstrated consistently high predictive performance across different molecular subtypes, including HR+/HER2−, HER2+, and triple-negative breast cancer (TNBC) (Table 3, Supplementary Table S6). The gene discussed is HR; the disease is triple-negative breast carcinoma.